Skip to main content
SpringerLink
Log in

Anti-angiogenics in Hepatocellular Cancer Therapy

  • Living reference work entry
  • First Online:
Tumor Angiogenesis

  • 159 Accesses

Abstract

Hepatocellular carcinoma (HCC) is one of the most common and deadly malignancies worldwide. HCC is a highly vascularized malignant tumor providing a rationale to consider angiogenesis as a therapeutic target. Anti-angiogenic strategies include locoregional and systemic treatments in HCC. Depending on the stage of the disease, different anti-angiogenic approaches are currently being employed in the treatment of HCC.

For patients at intermediate stage disease, transarterial chemoembolization (TACE) has been widely accepted as the standard of care and is the most common therapy for this patient group. TACE is a locoregional intervention, and its main mechanism of action is the embolization of the tumor-feeding arteries. For patients with advanced HCC, the multiprotein kinase inhibitors sorafenib and regorafenib provide systemic treatment options. Their efficacy in terms of survival prolongation has been shown in the palliative setting. Both drugs target among others the receptor of the vascular endothelial growth factor (VEGF), and their antitumor efficacy is believed to partly depend on the anti-angiogenic properties.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Abou-Alfa GK, Cheng AL, Meyer T, El-Khoueiry AB, Ikeda M, Chun HG, Furuse J et al (2015) Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426). J Clin Oncol 33

    Google Scholar 

  • Adhoute X, Penaranda G, Naude S, Raoul JL, Perrier H, Bayle O, Monnet O et al (2015) Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. J Hepatol 62:855–862

    Article  PubMed  Google Scholar 

  • Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, Galbraith S, Jeyaseelan R Sr et al (2010) The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 9:369–378

    Article  CAS  PubMed  Google Scholar 

  • Bosetti C, Turati F, La Vecchia C (2014) Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 28:753–770

    Article  PubMed  Google Scholar 

  • Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR et al (2016) Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 34:2046

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR et al (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57:821–829

    Article  CAS  PubMed  Google Scholar 

  • Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022

    Article  PubMed  PubMed Central  Google Scholar 

  • Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V et al (2013) Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer 49:3412–3419

    Article  CAS  PubMed  Google Scholar 

  • Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M et al (2015) Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 33:172–179

    Article  CAS  PubMed  Google Scholar 

  • Cappelli A, Cucchetti A, Cabibbo G, Mosconi C, Maida M, Attardo S, Pettinari I et al (2016) Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma. Liver Int 36(5):729–736

    Article  CAS  PubMed  Google Scholar 

  • Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34

    Article  CAS  PubMed  Google Scholar 

  • Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC et al (2013) Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 31:4067–4075

    Article  CAS  PubMed  Google Scholar 

  • El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365:1118–1127

    Article  CAS  PubMed  Google Scholar 

  • Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M et al (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10:794–800

    Article  CAS  PubMed  Google Scholar 

  • Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M et al (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10:794–800

    Article  CAS  PubMed  Google Scholar 

  • Fang P, Hu JH, Cheng ZG, Liu ZF, Wang JL, Jiao SC (2012) Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One 7

    Google Scholar 

  • Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, Breatta AD et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111:255–264

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Muller C, Heinzl H et al (2014) How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol 61:1287–1296

    Article  PubMed  Google Scholar 

  • Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Muller C, Heinzl H et al (2014) How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol 61:1287–1296

    Article  PubMed  Google Scholar 

  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90

    Article  PubMed  Google Scholar 

  • Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH et al (2013) Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31:3517–3524

    Article  CAS  PubMed  Google Scholar 

  • Kadalayil L, Benini R, Pallan L, O’Beirne J, Marelli L, Yu D, Hackshaw A et al (2013) A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 24:2565–2570

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kadalayil L, Benini R, Pallan L, O'Beirne J, Marelli L, Yu D, Hackshaw A et al (2013) A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 24:2565–2570

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116:1582–1595

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao LC, Abdalla EK et al (2011) Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 29:3892–3899

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, Xu Y et al (2009) Role of overexpression of CD151 and/or c-met in predicting prognosis of hepatocellular carcinoma. Hepatology 49:491–503

    Article  CAS  PubMed  Google Scholar 

  • Kirstein MM, Schweitzer N, Ay N, Boeck C, Lappas K, Hinrichs JB, Voigtlander T et al (2016) Experience from a real-life cohort: outcome of patients with hepatocellular carcinoma following transarterial chemoembolization. Scand J Gastroenterol:1–22

    Google Scholar 

  • Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52

    Article  PubMed  Google Scholar 

  • Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JFH (2016) Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 64:106–116

    Article  CAS  PubMed  Google Scholar 

  • Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW et al (2016) Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 64:1090–1098

    Article  CAS  PubMed  Google Scholar 

  • Lencioni R, Marrero J, Venook A, Ye SL, Kudo M (2010) Design and rationale for the non-interventional global investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with Sorafenib (GIDEON) study. Int J Clin Pract 64:1034–1041

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907–1917

    Article  PubMed  Google Scholar 

  • Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK et al (2013) Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31:3509–3516

    Article  CAS  PubMed  Google Scholar 

  • Llovet JM, Pena CEA, Lathia CD, Shan M, Meinhardt G, Bruix J, Grp SIS (2012) Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18:2290–2300

    Article  CAS  PubMed  Google Scholar 

  • Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739

    Article  PubMed  Google Scholar 

  • Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

    Article  CAS  PubMed  Google Scholar 

  • Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171

    Article  CAS  PubMed  Google Scholar 

  • Malek NP, Schmidt S, Huber P, Manns MP, Greten TF (2014) The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int 111:101–106

    PubMed  PubMed Central  Google Scholar 

  • Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, Davies N et al (2013) A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer 108:1252–1259

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M et al (2015) Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int 35:2155–2166

    Article  PubMed  PubMed Central  Google Scholar 

  • Park Y, Kim SU, Kim BK, Park JY, Kim do Y, Ahn SH, Park YE et al (2016) Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Liver Int 36:100–107

    Article  CAS  PubMed  Google Scholar 

  • Ravi S, Singal AK (2014) Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer. Core Evid 9:81–87

    PubMed  PubMed Central  Google Scholar 

  • Raymond E, Faivre S, Douillard J, Boucher E, Lim H, Kim J, Lanzalone S et al (2007) Phase II trial of the efficacy and safety of sunitinib malate monotherapy in unresectable hepatocellular carcinoma. Ann Oncol 18:Vii15–Vii15

    Google Scholar 

  • Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H et al (2013) Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 14:55–63

    Article  CAS  PubMed  Google Scholar 

  • Shim JH, Park JW, Kim JH, An M, Kong SY, Nam BH, Choi JI et al (2008) Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 99:2037–2044

    CAS  PubMed  Google Scholar 

  • Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Muller C, Heinzl H et al (2013) The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 57:2261–2273

    Article  CAS  PubMed  Google Scholar 

  • Verslype C, Cohn AL, Kelley RK, Yang TS, Su WC, Ramies DA, Lee Y et al (2012) Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 30

    Google Scholar 

  • Wang G, Liu Y, Zhou SF, Qiu P, Xu L, Wen P, Wen J et al (2016) Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. Hepatol Int 10:501–510

    Article  PubMed  Google Scholar 

  • Zeng J, Lv L, Mei ZC (2016) Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol 40(6):688–697

    Article  CAS  PubMed  Google Scholar 

  • Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, Weissinger F, et al. (2016) Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of REACH trial results by child-pugh score. JAMA Oncol

    Google Scholar 

  • Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP et al (2013) A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 19:6614–6623

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhu AX, Kang YK, Rosmorduc O, Evans TR, Santoro A, Ross P, Gane E et al (2016) Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with Sorafenib with or without Erlotinib in the SEARCH trial. Clin Cancer Res 22:4870–4879

    Article  CAS  PubMed  Google Scholar 

  • Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V et al (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27:3027–3035

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hepatology und Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany

    Martha M. Kirstein & Arndt Vogel

Authors
  1. Martha M. Kirstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arndt Vogel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arndt Vogel .

Editor information

Editors and Affiliations

  1. Tumor Biology Center, Freiburg, Baden-Württemberg, Germany

    Dieter Marmé

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this entry

Cite this entry

Kirstein, M.M., Vogel, A. (2017). Anti-angiogenics in Hepatocellular Cancer Therapy. In: Marmé, D. (eds) Tumor Angiogenesis. Springer, Cham. https://doi.org/10.1007/978-3-319-31215-6_23-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-31215-6_23-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-31215-6

  • Online ISBN: 978-3-319-31215-6

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation